News & Updates

Degarelix tied to BMD decrease in prostate cancer

07 Dec 2022

Treatment with degarelix results in a substantial reduction in bone mineral density (BMD) and an increase in bone turnover markers, reports a study.

Degarelix tied to BMD decrease in prostate cancer

07 Dec 2022

Cyclosporin may increase malignancy risk in psoriasis

07 Dec 2022

In psoriasis patients, treatment with cyclosporin may increase the risk of malignancy without nonmelanoma skin cancer, a recent study has found. Biologic or phototherapy have no such impact.

Cyclosporin may increase malignancy risk in psoriasis

07 Dec 2022

Smoking cessation intervention during lung screening may encourage quitting

05 Dec 2022 by

A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.

Smoking cessation intervention during lung screening may encourage quitting

05 Dec 2022

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

05 Dec 2022 by

In the second interim analysis of the PEARLS/KEYNOTE-091 study, adjuvant pembrolizumab monotherapy provided a clinically meaningful improvement in disease-free survival (DFS) in individuals with stage IB–IIIA non-small cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy (CT).

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

05 Dec 2022

Dip in serum cholesterol tied to higher pancreatic cancer risk

05 Dec 2022 by

A recent decrease in total cholesterol levels may signal an aggravated risk of pancreatic cancer, reports a study. On the other hand, high serum cholesterol in the preceding years may exert a protective effect against pancreatic cancer.

Dip in serum cholesterol tied to higher pancreatic cancer risk

05 Dec 2022

Original New Drug Application Approvals by US FDA (16 - 30 November 2022)

05 Dec 2022

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 November 2022)

05 Dec 2022

MELTUMP, SAMPUS rarely lead to metastatic malignancies

03 Dec 2022

There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.

MELTUMP, SAMPUS rarely lead to metastatic malignancies

03 Dec 2022

Colorectal polyps more common in sporadic ampullary adenoma

03 Dec 2022

Patients with sporadic ampullary tumours more commonly have colorectal polyps or neoplasia than healthy controls, a recent study has found.

Colorectal polyps more common in sporadic ampullary adenoma

03 Dec 2022

First-line serplulimab + chemo ups survival in extensive-stage SCLC

02 Dec 2022 by

The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.

First-line serplulimab + chemo ups survival in extensive-stage SCLC

02 Dec 2022

Pharmacogenomic profiling of paediatric AML informs precision medicine

02 Dec 2022 by

A study by the Chinese University of Hong Kong (CUHK) has found age-specific differences in drug responses and new gene-drug interactions in paediatric acute myeloid leukaemia (AML).

Pharmacogenomic profiling of paediatric AML informs precision medicine

02 Dec 2022

News & Updates

Filter by Specialty:

Specialty:

Degarelix tied to BMD decrease in prostate cancer

Degarelix tied to BMD decrease in prostate cancer

Cyclosporin may increase malignancy risk in psoriasis

Cyclosporin may increase malignancy risk in psoriasis

Smoking cessation intervention during lung screening may encourage quitting

Smoking cessation intervention during lung screening may encourage quitting

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

Pembrolizumab a novel treatment alternative for early-stage NSCLC?

Dip in serum cholesterol tied to higher pancreatic cancer risk

Dip in serum cholesterol tied to higher pancreatic cancer risk

Original New Drug Application Approvals by US FDA (16 - 30 November 2022)

Original New Drug Application Approvals by US FDA (16 - 30 November 2022)

MELTUMP, SAMPUS rarely lead to metastatic malignancies

MELTUMP, SAMPUS rarely lead to metastatic malignancies

Colorectal polyps more common in sporadic ampullary adenoma

Colorectal polyps more common in sporadic ampullary adenoma

First-line serplulimab + chemo ups survival in extensive-stage SCLC

First-line serplulimab + chemo ups survival in extensive-stage SCLC

Pharmacogenomic profiling of paediatric AML informs precision medicine

Pharmacogenomic profiling of paediatric AML informs precision medicine